MX2007005291A - Metodos para preparar compuestos de indazol. - Google Patents

Metodos para preparar compuestos de indazol.

Info

Publication number
MX2007005291A
MX2007005291A MX2007005291A MX2007005291A MX2007005291A MX 2007005291 A MX2007005291 A MX 2007005291A MX 2007005291 A MX2007005291 A MX 2007005291A MX 2007005291 A MX2007005291 A MX 2007005291A MX 2007005291 A MX2007005291 A MX 2007005291A
Authority
MX
Mexico
Prior art keywords
formula
compound
reaction
compounds
mixture
Prior art date
Application number
MX2007005291A
Other languages
English (en)
Spanish (es)
Inventor
Nebojsa Slobodan Stankovic
Brigitte Leigh Ewanicki
Erik Jon Flahive
Annie Judith Kasparian
Mark Bryan Mitchell
Michael David Perry
Stacy Ann O'neill-Slawecki
Neal William Sach
James Edward Saenz
Bing Shi
Jayaram Kasturi Srirangam
Qingping Tian
Shu Yu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2007005291A publication Critical patent/MX2007005291A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
MX2007005291A 2004-11-02 2005-10-21 Metodos para preparar compuestos de indazol. MX2007005291A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62463504P 2004-11-02 2004-11-02
US71707105P 2005-09-14 2005-09-14
PCT/IB2005/003297 WO2006048744A1 (en) 2004-11-02 2005-10-21 Methods of preparing indazole compounds

Publications (1)

Publication Number Publication Date
MX2007005291A true MX2007005291A (es) 2007-07-19

Family

ID=35744929

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005291A MX2007005291A (es) 2004-11-02 2005-10-21 Metodos para preparar compuestos de indazol.

Country Status (14)

Country Link
US (1) US7232910B2 (enExample)
EP (1) EP1809621A1 (enExample)
JP (1) JP2008518900A (enExample)
KR (1) KR20070058690A (enExample)
AR (1) AR051754A1 (enExample)
AU (1) AU2005300310A1 (enExample)
BR (1) BRPI0518203A2 (enExample)
CA (1) CA2586174A1 (enExample)
IL (1) IL182693A0 (enExample)
MX (1) MX2007005291A (enExample)
NO (1) NO20071619L (enExample)
RU (1) RU2007116107A (enExample)
TW (1) TWI294421B (enExample)
WO (1) WO2006048744A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679356A (zh) 2007-04-05 2010-03-24 辉瑞产品公司 适用于治疗哺乳动物异常细胞生长的6-[2-(甲基-氨甲酰基)苯基硫基]-3-e-[2-(吡啶-2-基)乙烯基]吲唑的晶型
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
EP2163544A1 (en) * 2008-09-16 2010-03-17 Pfizer, Inc. Methods of preparing indazole compounds
CA2949515C (en) 2009-01-08 2018-10-23 Axel Becker Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
TW201531309A (zh) 2011-09-30 2015-08-16 Pfizer N-甲基-2-〔3-((e)-2-吡啶-2-基-乙烯基)-1h-吲唑-6-基硫烷基〕苯甲醯胺之藥學組成物
JP2014533262A (ja) 2011-11-11 2014-12-11 ファイザー・インク 慢性骨髄性白血病を治療するためのn−メチル−2−[3−((e)−2−ピリジン−2−イル−ビニル)−1h−インダゾール−6−イルスルファニル]−ベンズアミド
US9899120B2 (en) 2012-11-02 2018-02-20 Nanotek Instruments, Inc. Graphene oxide-coated graphitic foil and processes for producing same
US10087073B2 (en) 2013-02-14 2018-10-02 Nanotek Instruments, Inc. Nano graphene platelet-reinforced composite heat sinks and process for producing same
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
HUE046727T2 (hu) * 2013-12-06 2020-03-30 Vertex Pharma Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
US10570202B2 (en) 2014-02-04 2020-02-25 Pfizer Inc. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
RU2667486C2 (ru) * 2014-03-31 2018-09-20 Сэндзю Фармацевтикал Ко., Лтд. Производное алкинилиндазола и его применение
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
WO2016108106A1 (en) * 2014-12-29 2016-07-07 Shilpa Medicare Limited An improved process for preparation of axitinib
KR20170132171A (ko) 2015-02-26 2017-12-01 메르크 파텐트 게엠베하 암 치료를 위한 pd­1 / pd­l1 저해제
US9580406B2 (en) 2015-04-28 2017-02-28 Signa S.A. De C.V. Processes for the preparation of axitinib
RU2766890C2 (ru) 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1
BR112019006504A2 (pt) 2016-10-06 2019-06-25 Pfizer Inc. regime de dosagem de avelumabe para o tratamento de câncer
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
ES2982700T3 (es) 2019-04-18 2024-10-17 Synthon Bv Proceso para preparar axitinib, proceso para purificar el producto intermedio 2-((3-yodo-1H-indazol-6-il)tio)-n-metilbenzamida, proceso para purificar axitinib a través de la sal HCI de axitinib, forma sólida de la sal HCI de axitinib
IL315262A (en) 2022-03-03 2024-10-01 Pfizer Multiple specific antibodies related to IL-4, IL-13 and/or TSLP and their uses
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
KR101099281B1 (ko) * 2003-03-03 2011-12-26 어레이 바이오파마 인크. p38 억제제 및 그의 사용 방법
KR20050119671A (ko) * 2003-04-03 2005-12-21 화이자 인코포레이티드 Ag013736을 포함하는 제형
US20080274192A1 (en) 2005-05-19 2008-11-06 Pfizer Inc. Pharmaceutical Compositions Comprising an Amorphous Form of a Vegf-R-Inhibitor

Also Published As

Publication number Publication date
WO2006048744A1 (en) 2006-05-11
BRPI0518203A2 (pt) 2009-03-10
TWI294421B (en) 2008-03-11
KR20070058690A (ko) 2007-06-08
RU2007116107A (ru) 2008-11-10
EP1809621A1 (en) 2007-07-25
US7232910B2 (en) 2007-06-19
TW200621721A (en) 2006-07-01
AR051754A1 (es) 2007-02-07
IL182693A0 (en) 2007-09-20
US20060094881A1 (en) 2006-05-04
CA2586174A1 (en) 2006-05-11
NO20071619L (no) 2007-04-25
JP2008518900A (ja) 2008-06-05
AU2005300310A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
EP1809621A1 (en) Methods of preparing indazole compounds
US20070203196A1 (en) Methods of preparing indazole compounds
CA2349330C (en) Nitrogen containing heterobicycles as factor xa inhibitors
TWI603970B (zh) 雜環化合物之合成
AU2011336214B2 (en) KAT II inhibitors
AU2005300311A1 (en) Methods for preparing indazole compounds
JP4932065B2 (ja) βセクレターゼ阻害剤としてのラクタム
TW201321378A (zh) 用於製造氮雜吲哚之方法及中間物
JP2013508350A (ja) ガンマ−セクレターゼモジュレーターとしての新規なヘテロアリールイミダゾールおよびヘテロアリールトリアゾール
JP5722880B2 (ja) 1H−ピラゾロ[4,3−c]イソキノリン誘導体、これらの調製およびこれらの治療上の使用
CN122029160A (zh) 制备pi3k抑制剂的方法
JP2013523806A (ja) スルタム化合物
EP2163544A1 (en) Methods of preparing indazole compounds
CN114026095A (zh) 用于制备4-苯基-5-烷氧基羰基-2-噻唑-2-基-1,4-二氢嘧啶-6-基]甲基]-3-氧代-5,6,8,8a-四氢-1H-咪唑并[1,5-a]吡嗪-2-基]-甲酸的替代方法
CN121620512A (zh) 奥布替尼的制备方法及其中间体化合物
US20050090668A1 (en) Preparation of 5-hydroxy-6-oxo-1,6-dihydropyrimidine compounds
HK40114080A (en) Methods of preparing substituted pyrazolopyrimidines
HK40061337A (en) Alternative process for the preparation of [[[4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid
HK1163066A (en) Lactams as beta secretase inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal